Keimyung University, abbreviated as KMU or Keimyung, is a private university located in Daegu, the fourth largest city in South Korea. The university takes roots from Jejungwon founded in 1899.

During the past decade, Keimyung University Dongsan Medical Center conducted 220 clinical trials. In the 10-year time frame, 220 clinical trials started and 49 clinical trials were completed, i.e. on average, 22.3% percent of trials that started reached the finish line to date. In the past 5 years, 91 clinical trials started and 36 clinical trials were completed. i.e. 39.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Keimyung University Dongsan Medical Center" #1 sponsor was "Seung-Jung Park" with 33 trials, followed by "Keimyung University Dongsan Medical Center" with 16 trials sponsored, "Pfizer" with 15 trials sponsored, "Hoffmann-La Roche" with 14 trials sponsored and "Boehringer Ingelheim" with 14 trials sponsored. Other sponsors include 217 different institutions and companies that sponsored additional 115 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Keimyung University Dongsan Medical Center" #1 collaborator was "CardioVascular Research Foundation, Korea" with 41 trials as a collaborator, "Seoul National University Hospital" with 13 trials as a collaborator, "Keimyung University Dongsan Medical Center" with 11 trials as a collaborator, "Ulsan University Hospital" with 10 trials as a collaborator and "Inje University" with 8 trials as a collaborator. Other collaborators include 243 different institutions and companies that were collaborators in the rest 181 trials.

According to Clinical.Site data, the most researched conditions in "Keimyung University Dongsan Medical Center" are "Coronary Artery Disease" (40 trials), "Atrial Fibrillation" (15 trials), "Gastric Cancer" (11 trials), "Coronary Disease" (9 trials) and "Hypertension" (7 trials). Many other conditions were trialed in "Keimyung University Dongsan Medical Center" in a lesser frequency.

Most popular intervention types in "Keimyung University Dongsan Medical Center" are "Drug" (184 trials), "Device" (49 trials), "Other" (28 trials), "Procedure" (25 trials) and "Biological" (22 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "Paclitaxel" (8 trials), "Carboplatin" (6 trials), "Cisplatin" (5 trials) and "Quality-of-Life Assessment" (5 trials). Other intervention names were less common.

The vast majority of trials in "Keimyung University Dongsan Medical Center" are 278 trials for "All" genders, 23 trials for "Female" genders and 7 trials for "Male" genders.

Currently, there are NaN active trials in "Keimyung University Dongsan Medical Center". 1 are not yet recruiting, 66 are recruiting, 43 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 133 completed trials in Keimyung University Dongsan Medical Center, undefined suspended trials, and 22 terminated clinical trials to date.

Out of the total trials that were conducted in Keimyung University Dongsan Medical Center, 13 "Phase 1" clinical trials were conducted, 54 "Phase 2" clinical trials and 83 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 50 trials, and there were also 36 trials that are defined as “Not Applicable".